WHIM

X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022

Retrieved on: 
Thursday, October 20, 2022
U.S. Securities and Exchange Commission, Therapy, Risk, SEC, Webcast, Cyclic neutropenia, WM, Patient, Biology, Research, Security (finance), Partnership, Cancer, Private Securities Litigation Reform Act, B-cell lymphoma, Immune system, WHIM syndrome, Immunodeficiency, Safety, Medication, GLOBE, WHIM, Clinical trial, CXCR4, Forward-looking statement, ID, Lists of diseases, Pharmaceutical industry

X4 will host a conference call and webcast on the same day at 8:30 a.m.

Key Points: 
  • X4 will host a conference call and webcast on the same day at 8:30 a.m.
  • ET to discuss important upcoming milestones, including the pending release of results from the companys Phase 3 trial of its lead candidate mavorixafor in the treatment of WHIM syndrome.
  • The conference call can be accessed by dialing 1-855-327-6837 from the United States or 1-631-891-4304 internationally, followed by the conference ID: 10020371.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals website at www.x4pharma.com .

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

Retrieved on: 
Tuesday, September 27, 2022
Lists of diseases, Neutropenia, Therapy, WHIM syndrome, Safety, Infection, ET, Trial of the century, Q&A, ANC, Risk, Neutrophil, WM, Immunodeficiency, Blood, Population, Private Securities Litigation Reform Act, Partnership, Forward-looking statement, U.S. Securities and Exchange Commission, Patient, Degenerative disease, Clinical trial, Cancer, B-cell lymphoma, Biology, Quality of life, CN, Bone marrow, Cell, Medication, Birth, G-CSF, Research, Security (finance), GLOBE, SEC, CXCR4, WHIM, Immune system, Severe congenital neutropenia, Cyclic neutropenia, Dentistry, Pharmaceutical industry

In addition, we are encouraged by the results of three exploratory sub-analyses we completed assessing the potential of mavorixafor to treat chronic neutropenia as monotherapy or concurrently with G-CSF.

Key Points: 
  • In addition, we are encouraged by the results of three exploratory sub-analyses we completed assessing the potential of mavorixafor to treat chronic neutropenia as monotherapy or concurrently with G-CSF.
  • We believe these data support the further study of mavorixafors potential to enable patients to reduce or even discontinue G-CSF treatment.
  • We anticipate this amended trial to begin generating additional clinical data in the first half of 2023.
  • X4 will host an investor webinar to present and discuss the new data today from 8:00 - 9:15 am ET.

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

Retrieved on: 
Wednesday, August 31, 2022
G-CSF, B-cell lymphoma, Partnership, Security (finance), Safety, Cancer, CXCR4, Trial of the century, Lists of diseases, Research, Neutropenia, Medication, Immunodeficiency, WHIM, WHIM syndrome, SEC, U.S. Securities and Exchange Commission, Cyclic neutropenia, GLOBE, WM, Biology, Immune system, Therapy, Risk, Clinical trial, Private Securities Litigation Reform Act, Q&A, Forward-looking statement, Patient, Pharmaceutical industry, Infection, Hypogammaglobulinemia, Myelokathexis

Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.

Key Points: 
  • Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.
  • The clinical trial ( NCT04154488 ) is a proof-of-concept Phase 1b open-label, multicenter study designed to assess the safety and tolerability of daily, oral mavorixafor with or without G-CSF, in participants with chronic neutropenic disorders including severe congenital, idiopathic, or cyclic neutropenia.
  • Participants were dosed with a single dose of oral mavorixafor to assess the magnitude of treatment response.
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.

X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth Conference

Retrieved on: 
Monday, August 8, 2022
GLOBE, Cancer, Cyclic neutropenia, B-cell lymphoma, Immunodeficiency, WHIM, Research, Patient, WM, WHIM syndrome, Therapy, Partnership, Safety, Biology, CXCR4, Canaccord Genuity, Medication, Conference, Immune system, Pharmaceutical industry

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.

Key Points: 
  • BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.
  • A live webcast of the presentation will be available on the investors section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcast, this event will remain archived on the X4 Pharmaceuticals website for approximately 90 days.
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.

Common Warts Drug Pipeline Report 2022 Featuring Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, & NIELSEN BioSciences - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Health, Pharmaceutical, Wart, Molluscum contagiosum, WHIM syndrome, Route of administration, Patient, WHIM, CXCR4, GMP, Cantharidin, Administration, Therapy, Route, Pharmaceutical industry, Vaccine

The "Common Warts - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Common Warts - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This ''Common Warts - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Warts.
  • The companies which have their Common Warts drug candidates in the most advanced stage, i.e phase III include X4 Pharmaceuticals
    Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022

Retrieved on: 
Tuesday, July 26, 2022
WHIM, United, Medication, GLOBE, WM, WHIM syndrome, Immunodeficiency, Research, Partnership, B-cell lymphoma, Immune system, Safety, Cancer, Webcast, Company, Patient, Cyclic neutropenia, Biology, Therapy, CXCR4, Pharmaceutical industry

The Company will host a conference call and webcast on the same day at8:30 a.m. ETto discuss these financial results and business highlights.

Key Points: 
  • The Company will host a conference call and webcast on the same day at8:30 a.m. ETto discuss these financial results and business highlights.
  • The conference call can be accessed by dialing 1-855-327-6837 fromthe United Statesor 1-631-891-4304 internationally, followed by the conference ID: 10019589.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals website at www.x4pharma.com .
  • Following the completion of the call, a webcast replay of the conference call will be available on the website.

X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

Retrieved on: 
Wednesday, July 20, 2022
WHIM, Traffic barrier, GLOBE, WM, Importance, MYD88, U.S. Securities and Exchange Commission, CN, Orphan, WHIM syndrome, Wart, SEC, Immunodeficiency, Research, Forward-looking statement, Partnership, Leukemia, Toxicology, Workforce, Private Securities Litigation Reform Act, NDA, Lymphoma, B-cell lymphoma, Patent, Risk, Immune system, Safety, COVID-19, Cancer, Achievement, Clinical trial, FDA, Security (finance), Patient, Cyclic neutropenia, Biology, Therapy, CXCR4, IND, Pharmaceutical industry, Infection, Hypogammaglobulinemia

BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today announced an update to its strategic priorities that includes streamlining resources to focus on advancing its lead clinical candidate, mavorixafor, in WHIM syndrome and other chronic neutropenic disorders, while progressing its clinical and pre-clinical oncology programs only via potential partnership(s).

Key Points: 
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.
  • Our lead clinical candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
  • Any forward-looking statements in this press release are based on management's current expectations and beliefs.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, January 5, 2022
Safety, SCN, Therapy, Research, Patient, Immune system, Cancer, CXCR4, Medication, Immunodeficiency, GLOBE, Biology, WHIM, Employment, WHIM syndrome, Financial compensation, Pharmaceutical industry

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.

Key Points: 
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.
  • The inducement awards consist of options to purchase an aggregate of 37,650 shares of X4s common stock.
  • These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, December 1, 2021
Patient, Safety, Financial compensation, WHIM, Biology, Cancer, Immunodeficiency, CXCR4, Therapy, Research, WHIM syndrome, GLOBE, Medication, Immune system, R rating, Employment, SCN, Pharmaceutical industry

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.

Key Points: 
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.
  • The inducement awards consist of options to purchase an aggregate of 17,000 shares of X4s common stock and restricted stock units covering 25,000 shares of X4s common stock.
  • These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, November 1, 2021
Safety, Medication, Biology, Research, WHIM, Cancer, SCN, Patient, Immunodeficiency, Financial compensation, Immune system, Therapy, Employment, GLOBE, WHIM syndrome, CXCR4, Pharmaceutical industry

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.

Key Points: 
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.
  • The inducement awards consist of options to purchase an aggregate of 11,050 shares of X4s common stock.
  • These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.